信迪利单抗联合盐酸安罗替尼对晚期非小细胞肺癌患者血清免疫指标和肿瘤标志物水平的影响

Effect of sintilimab combined with anlotinib hydrochloride on serum immune indexes and tumor markers in patients with advanced non-small cell lung cancer

目的:探讨信迪利单抗联合盐酸安罗替尼对晚期非小细胞肺癌症患者血清免疫指标和肿瘤标志物水平的影响。方法:选取80例晚期非小细胞肺癌患者为研究对象,并随机分入研究组(n=40)和对照组(n=40);对照组患者采用口服盐酸安罗替尼治疗,研究组患者采用信迪利单抗联合盐酸安罗替尼治疗;比较两组临床疗效、血清免疫指标、肿瘤标志物水平以及不良反应发生情况。结果:临床疗效指标中,研究组客观缓解率与对照组比较无统计学意义(P>0.05),疾病控制率高于对照组(P<0.05)。干预后两组CD4+、CD4+/CD8+均高于干预前,且研究组高于对照组(P<0.05);两组CD8+均低于干预前,且研究组低于对照组(P<0.05);两组MMP2、VEGF、TIMP–1、CY211表达水平均低于干预前,且研究组低于对照组(P<0.05)。两组不良反应发生率比较无统计学意义(P>0.05)。结论:信迪利单抗联合盐酸安罗替尼在晚期非小细胞肺癌患者中应用可改善患者免疫水平,降低肿瘤标志物水平,疗效显著且具有一定安全性。

Objective:To investigate the effects of the combination of sintilimab and anlotinib hydrochloride on serum immunological indicators and tumor marker levels in patients with advanced non-small cell lung cancer.Methods:80 patients with advanced non-small cell lung cancer were selected as the study subjects and randomly assigned to the study group(n=40)and control group(n=40).The control group patients were treated with oral anlotinib,while the study group patients were treated with the combination of sintilimab and anlotinib.The clinical efficacy,serum immunological indicators,tumor marker levels,and adverse reaction incidence were compared between the two groups.Results:In terms of clinical efficacy indicators,there was no significant difference in objective response rate between the study group and the control group(P>0.05),but the disease control rate was higher in the control group(P<0.05).After intervention,both groups had higher CD4+and CD4+/CD8+levels than before intervention,with the study group having higher levels than the control group(P<0.05).Both groups had lower CD8+levels than before intervention,with the study group having lower levels than the control group(P<0.05).The expression levels of MMP2,VEGF,TIMP–1,and CY211 were all lower than before intervention in both groups,with the study group having lower levels than the control group(P<0.05).There was no significant difference in adverse reaction incidence between the two groups(P>0.05).Conclusion:The combination of sintilimab and anlotinib hydrochloride can improve patient immunological levels and reduce tumor marker levels in patients with advanced non-small cell lung cancer.The treatment is effective and has certain safety.